{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T02:57:53Z","timestamp":1790477873944,"version":"4.1.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,5,20]]},"DOI":"10.7759\/cureus.84468","type":"journal-article","created":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T12:30:25Z","timestamp":1747744225000},"source":"Crossref","is-referenced-by-count":2,"title":["Decoding FDA Labeling of Prescription Digital Therapeutics: A Cross-Sectional Regulatory Study"],"prefix":"10.7759","author":[{"given":"Shaheen E","family":"Lakhan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.82793","article-title":"When software becomes medicine: ignoring it may soon be malpractice","volume":"17","author":"Lakhan SE","year":"2025","unstructured":"Lakhan SE. When software becomes medicine: ignoring it may soon be malpractice. Cureus. 2025, 17:e82793. 10.7759\/cureus.82793","journal-title":"Cureus"},{"key":"ref2","unstructured":"FDA. Medical devices. Digital health center of excellence. Software as a medical device (SaMD). (2018). Accessed. May 7, 2025: https:\/\/www.fda.gov\/medical-devices\/digital-health-center-excellence\/software-medical-device-samd."},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2024.30.11.1318","article-title":"Unlocking the potential of digital therapeutics: the need for consistent and granular inclusion in drug compendia for managed care","volume":"30","author":"Johnson A","year":"2024","unstructured":"Johnson A, Bartels R, Honcz J, Graff JS, Skelton JB. Unlocking the potential of digital therapeutics: the need for consistent and granular inclusion in drug compendia for managed care. J Manag Care Spec Pharm. 2024, 30:1318-26. 10.18553\/jmcp.2024.30.11.1318","journal-title":"J Manag Care Spec Pharm"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1038\/s41746-023-00777-z","article-title":"Digital therapeutics from bench to bedside","volume":"6","author":"Wang C","year":"2023","unstructured":"Wang C, Lee C, Shin H. Digital therapeutics from bench to bedside. NPJ Digit Med. 2023, 6:38. 10.1038\/s41746-023-00777-z","journal-title":"NPJ Digit Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.8832","article-title":"FDA regulation of mobile medical apps","volume":"320","author":"Shuren J","year":"2018","unstructured":"Shuren J, Patel B, Gottlieb S. FDA regulation of mobile medical apps. JAMA. 2018, 320:337-8. 10.1001\/jama.2018.8832","journal-title":"JAMA"},{"key":"ref6","unstructured":"FDA. Device classification under Section 513(f)(2)(De Novo). Device name. CT-132. (2025). Accessed: May 7, 2025: https:\/\/www.accessdata.fda.gov\/scripts\/cdrh\/cfdocs\/cfpmn\/denovo.cfm?id=DEN240064."},{"key":"ref7","unstructured":"FDA. Device classification under Section 513(f)(2)(De Novo). Device name. AspyreRx. (2025). Accessed: May 7, 2025: https:\/\/www.accessdata.fda.gov\/scripts\/cdrh\/cfdocs\/cfpmn\/denovo.cfm?id=DEN220058."},{"key":"ref8","unstructured":"FDA. Device classification under Section 513(f)(2)(De Novo). Device name. EndeavorRx. (2025). Accessed: May 7, 2025: https:\/\/www.accessdata.fda.gov\/scripts\/cdrh\/cfdocs\/cfpmn\/denovo.cfm?id=DEN200026."},{"key":"ref9","unstructured":"FDA. Device classification under Section 513(f)(2)(De Novo). Device name. reSET. (2025). Accessed: May 7, 2025: https:\/\/www.accessdata.fda.gov\/scripts\/cdrh\/cfdocs\/cfpmn\/denovo.cfm?id=DEN160018."},{"key":"ref10","unstructured":"FDA. Device classification under Section 513(f)(2)(De Novo). Device name. Stanza. (2025). Accessed: May 7, 2025: https:\/\/www.accessdata.fda.gov\/scripts\/cdrh\/cfdocs\/cfpmn\/denovo.cfm?id=DEN220083."},{"key":"ref11","unstructured":"FDA. 510(k) premarket notification. Device name. Daylight. (2025). Accessed: May 7, 2025: https:\/\/www.accessdata.fda.gov\/scripts\/cdrh\/cfdocs\/cfPMN\/pmn.cfm?ID=K233872."},{"key":"ref12","unstructured":"FDA. 510(k) premarket notification. Device name. MamaLift Plus. (2025). Accessed: May 7, 2025: https:\/\/www.accessdata.fda.gov\/scripts\/cdrh\/cfdocs\/cfPMN\/pmn.cfm?ID=K223515."},{"key":"ref13","unstructured":"FDA. 510(k) premarket notification. Device name. Mahana Parallel Digital Cognitive Behavioral Therapy (CBT) mobile application for irritable bowel syndrome (IBS). (2025). Accessed: May 7, 2025: https:\/\/www.accessdata.fda.gov\/scripts\/cdrh\/cfdocs\/cfPMN\/pmn.cfm?ID=K211372."},{"key":"ref14","unstructured":"FDA. 510(k) premarket notification. Device name. Regulora. (2025). Accessed: May 7, 2025: https:\/\/www.accessdata.fda.gov\/scripts\/cdrh\/cfdocs\/cfPMN\/pmn.cfm?ID=K211463."},{"key":"ref15","unstructured":"FDA. 510(k) premarket notification. Device name. Rejoyn. (2025). Accessed: May 7, 2025: https:\/\/www.accessdata.fda.gov\/scripts\/cdrh\/cfdocs\/cfPMN\/pmn.cfm?ID=K231209."},{"key":"ref16","unstructured":"FDA. 510(k) premarket notification. Device name. reSET-O. (2025). Accessed: May 7, 2025: https:\/\/www.accessdata.fda.gov\/scripts\/cdrh\/cfdocs\/cfPMN\/pmn.cfm?ID=K173681."},{"key":"ref17","unstructured":"FDA. 510(k) premarket notification. Device name. Sleepio. (2025). Accessed: May 7, 2025: https:\/\/www.accessdata.fda.gov\/scripts\/cdrh\/cfdocs\/cfPMN\/pmn.cfm?ID=K233577."},{"key":"ref18","unstructured":"FDA. 510(k) premarket notification. Device name. Somryst. (2025). Accessed: May 7, 2025: https:\/\/www.accessdata.fda.gov\/scripts\/cdrh\/cfdocs\/cfPMN\/pmn.cfm?ID=K191716."},{"key":"ref19","unstructured":"FDA. Medical devices. Products and medical procedures. Device approvals and clearances. (2023). Accessed. May 7, 2025: https:\/\/www.fda.gov\/medical-devices\/products-and-medical-procedures\/device-approvals-and-clearances."},{"key":"ref20","unstructured":"FDA. Device classification under Section 513(f)(2)(De Novo). Device name. Luminopia One. (2021). Accessed: May 7, 2025: https:\/\/www.accessdata.fda.gov\/scripts\/cdrh\/cfdocs\/cfpmn\/denovo.cfm?id=DEN210005."},{"key":"ref21","unstructured":"FDA. Device Classification Under Section 513(f)(2)(De Novo). Device Name. NightWare Kit, Apple iPhone, Apple Watch, Apple iPhone Charging Cable, Apple Watch Charging Cable. (2020). Accessed: May 7, 2025: https:\/\/www.accessdata.fda.gov\/scripts\/cdrh\/cfdocs\/cfpmn\/denovo.cfm?id=DEN200033."},{"key":"ref22","unstructured":"WHO. International Classification of Diseases 11th revision browser. (2025). Accessed. May 7, 2025: https:\/\/icd.who.int\/browse\/2025-01\/mms\/en."},{"key":"ref23","unstructured":"FDA. Pediatric medical devices. (2024). Accessed. May 7, 2025: https:\/\/www.fda.gov\/medical-devices\/products-and-medical-procedures\/pediatric-medical-devices."},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.3389\/fdgth.2023.1086219","article-title":"FDA regulations and prescription digital therapeutics: evolving with the technologies they regulate","volume":"5","author":"Watson A","year":"2023","unstructured":"Watson A, Chapman R, Shafai G, Maricich YA. FDA regulations and prescription digital therapeutics: evolving with the technologies they regulate. Front Digit Health. 2023, 5:1086219. 10.3389\/fdgth.2023.1086219","journal-title":"Front Digit Health"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/S2589-7500(23)00244-3","article-title":"Characterisation of digital therapeutic clinical trials: a systematic review with natural language processing","volume":"6","author":"Miao BY","year":"2024","unstructured":"Miao BY, Sushil M, Xu A, et al.. Characterisation of digital therapeutic clinical trials: a systematic review with natural language processing. Lancet Digit Health. 2024, 6:e222-9. 10.1016\/S2589-7500(23)00244-3","journal-title":"Lancet Digit Health"},{"key":"ref26","unstructured":"Digital Therapeutics Alliance. Guidance to industry. classification of digital health technologies. (2023). Accessed: May 11, 2025: https:\/\/dtxalliance.org\/wp-content\/uploads\/2023\/06\/Guidance-to-Industry-Classification-of-Digital-Health-Technologies...."},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.3390\/pharmacy13010019","article-title":"Therapeutic evaluation and utilization analysis of mental health prescription digital therapeutics within the current regulatory landscape","volume":"13","author":"Xia SH","year":"2025","unstructured":"Xia SH, Narayanan MM, Swamy V, Franson K. Therapeutic evaluation and utilization analysis of mental health prescription digital therapeutics within the current regulatory landscape. Pharmacy (Basel). 2025, 13:10.3390\/pharmacy13010019","journal-title":"Pharmacy (Basel)"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2021.12.011","article-title":"Heterologous COVID-19 vaccination in Spain: a case study of individual autonomy in the real world","volume":"25","author":"Dal-R\u00e9 R","year":"2022","unstructured":"Dal-R\u00e9 R, Farr\u00e9 M, Lucena MI. Heterologous COVID-19 vaccination in Spain: a case study of individual autonomy in the real world. Value Health. 2022, 25:770-2. 10.1016\/j.jval.2021.12.011","journal-title":"Value Health"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2018.24.12.1240","article-title":"Discrepancies between FDA-required labeling and evidence that payers cite in drug coverage policies","volume":"24","author":"Chambers JD","year":"2018","unstructured":"Chambers JD, Pope EF, Wilkinson CL, Neumann PJ. Discrepancies between FDA-required labeling and evidence that payers cite in drug coverage policies. J Manag Care Spec Pharm. 2018, 24:1240-6. 10.18553\/jmcp.2018.24.12.1240","journal-title":"J Manag Care Spec Pharm"},{"key":"ref30","article-title":"Drug labeling","author":"Lopez MJ","year":"2024","unstructured":"Lopez MJ, Patel P. Drug labeling. StatPearls [Internet]. StatPearls Publishing, Treasure Island, FL; 2024."}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/370632-decoding-fda-labeling-of-prescription-digital-therapeutics-a-cross-sectional-regulatory-study","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T12:30:29Z","timestamp":1747744229000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/370632-decoding-fda-labeling-of-prescription-digital-therapeutics-a-cross-sectional-regulatory-study"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,20]]},"references-count":30,"URL":"https:\/\/doi.org\/10.7759\/cureus.84468","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5,20]]}}}